[go: up one dir, main page]

UY25710A1 - Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial - Google Patents

Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial

Info

Publication number
UY25710A1
UY25710A1 UY25710A UY25710A UY25710A1 UY 25710 A1 UY25710 A1 UY 25710A1 UY 25710 A UY25710 A UY 25710A UY 25710 A UY25710 A UY 25710A UY 25710 A1 UY25710 A1 UY 25710A1
Authority
UY
Uruguay
Prior art keywords
drug
agent
forming polymer
gas
composition
Prior art date
Application number
UY25710A
Other languages
English (en)
Inventor
John N Staniforth
Himadri Sen
Naresh Talwar
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/152,932 external-priority patent/US6261601B1/en
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of UY25710A1 publication Critical patent/UY25710A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Composicion farmaceutica en forma de tabletas o capsulas que provee una combinacion de control temporal y espacial de la liberacion de una droga a un paciente para resultados terapeuticos efectivos. Esta composicion comprende una droga, un componente generador de gas, un agente dilatador, un agente viscoso y opcionalmente un polimero formador de gel. La composición farmacéutica donde la droga es seleccionda del grupo que esta compuesto por drogas terapéuticas, quimioterapéuticas, antibióticas, anticancerígenas, antimicosas, antifibrales, antiulceras, antivirales, antigota, cardiovasculares, antiflamatorio, respirarorias, inmunosupresoras, y reductoras de grasa, en dicha composición el generador de gas es un silfito, un carbonato, o una sal de bicarbonato, el agente dilatador comprende un superdesintegrador, el agente viscoso contiene una goma de carbohidratos, y el polimero formador comprende una sal soluble en agua de por lo menos un ácido poliurónico. Ini cialmente el agente viscoso y luego el gas el polimero formador de gel, forman una matriz de gel hidratada que ocluye el gas, causando que la tableta o cápsula floten para ser retenidas en el estomago o en la parte alta del intestino delgado (control espacial). Al mismo tiempo la matriz de gel hidratado crea un camino de difusión tortuoso para la droga, lo que resulta en un liberación sostenida de la droga (control temporal). Una formulación, preferida, de ciprofloxacin administrada una sola vez al día comprende 69,9% de base de ciprofloxacin, 0,34% de alginato de sodio, 1,03% de goma jántica, 13,7% de bicarbonato de sodio, 12,1% de polivinilpirrolidona de enlace cruzado, y opcionalmente otros excipientes farmacéuticos, la formulación está en forma de tabletas recubiertas o no, o en cápsulas.
UY25710A 1998-09-14 1999-09-14 Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial UY25710A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/152,932 US6261601B1 (en) 1997-09-19 1998-09-14 Orally administered controlled drug delivery system providing temporal and spatial control

Publications (1)

Publication Number Publication Date
UY25710A1 true UY25710A1 (es) 2000-03-31

Family

ID=22545063

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25710A UY25710A1 (es) 1998-09-14 1999-09-14 Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial

Country Status (41)

Country Link
EP (2) EP1281397A1 (es)
JP (1) JP2002524494A (es)
CN (1) CN1186013C (es)
AP (1) AP1659A (es)
AR (1) AR022672A1 (es)
AT (1) ATE245414T1 (es)
AU (1) AU758324B2 (es)
BG (1) BG105339A (es)
BR (1) BR9913696A (es)
CA (1) CA2343760A1 (es)
CO (1) CO5130022A1 (es)
CU (1) CU23040A3 (es)
CZ (1) CZ2001901A3 (es)
DE (1) DE69909801T2 (es)
DK (1) DK1107741T3 (es)
EA (2) EA004443B1 (es)
EE (1) EE200100153A (es)
ES (1) ES2204098T3 (es)
GE (1) GEP20043216B (es)
HK (1) HK1037967A1 (es)
HR (1) HRP20010187B1 (es)
HU (1) HUP0103632A3 (es)
ID (1) ID29843A (es)
IL (1) IL141977A0 (es)
IS (1) IS5885A (es)
MX (1) MXPA01002634A (es)
MY (1) MY127952A (es)
NO (1) NO20011276L (es)
NZ (2) NZ510487A (es)
OA (1) OA11652A (es)
PE (1) PE20001058A1 (es)
PL (1) PL346798A1 (es)
PT (1) PT1107741E (es)
SI (1) SI1107741T1 (es)
SK (1) SK285478B6 (es)
SV (1) SV1999000152A (es)
TR (1) TR200100731T2 (es)
UA (1) UA73287C2 (es)
UY (1) UY25710A1 (es)
WO (1) WO2000015198A1 (es)
ZA (1) ZA995839B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0204417A3 (en) * 2000-03-03 2005-03-29 Ranbaxy Lab Ltd Oral ciprofloxacin-composition of controlled release
AU2006202275A1 (en) * 2000-06-26 2006-06-22 Bayer Healthcare Ag Sustained-release preparations of quinolone antibiotics and method for preparation thereof
DE10031043A1 (de) 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
BR0113055A (pt) 2000-08-08 2003-07-08 Daiichi Seiyaku Co Preparação sólida altamente absorvìvel
IN192748B (es) * 2000-08-29 2004-05-15 Ranbaxy Lab Ltd
EP1347748A2 (en) 2000-12-05 2003-10-01 MacGregor, Alexander Hydrostatic delivery system for controlled delivery of agent
MXPA03012041A (es) 2001-07-04 2004-03-26 Sun Pharmaceutical Ind Ltd Sistema de administracion controlada de farmacos de retencion gastrica.
IL160363A0 (en) * 2001-08-16 2004-07-25 Oregon State Expandable gastric retention device
WO2003017981A1 (en) * 2001-08-29 2003-03-06 Ranbaxy Laboratories Limited Controlled release formulation of clarithromycin or tinidazol
CA2466032A1 (en) * 2001-10-29 2003-05-08 Laure Patricia Ouadji Njiki Methods and dosage forms for improving the bioavailability of therapeutic agents
JP4882200B2 (ja) * 2001-11-13 2012-02-22 アステラス製薬株式会社 水溶性薬物徐放化技術
PT1461017E (pt) * 2001-11-19 2006-07-31 Lupin Ltd Composicao farmaceutica para a libertacao controlada de um antibiotico beta-lactamico
DE60219965T2 (de) * 2002-04-23 2008-01-17 Lupin Ltd., Mumbai Lang wirkende zusammensetzungen enthaltend zidovudine und/oder lamivudine
WO2005018613A1 (de) * 2003-08-26 2005-03-03 Mandapro Ag Pellets für die orale applikation von pharmazeutischen wirkstoffen
DE102004042139B4 (de) * 2004-08-31 2009-06-10 Aristocon Verwaltungs- Gmbh Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
GB0501810D0 (en) * 2005-01-28 2005-03-09 Pharmakodex Ltd Chemotherapeutic formulations
JP2009500318A (ja) * 2005-06-29 2009-01-08 パナセア バイオテック リミテッド 新規な徐放性医薬組成物とその製法
ATE396710T1 (de) * 2005-07-19 2008-06-15 Ethypharm Sa Gastroretentive zusammensetzungen und verfahren zur herstellung
GB0515492D0 (en) * 2005-07-28 2005-08-31 Reckitt Benckiser Healthcare Improvements in or relating to compositions,articles and methods
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
ZA200903854B (en) * 2008-06-19 2011-02-23 Univ Of The Witwatesrand Johannesburg A gastroretentive pharmaceutical dosage form
KR20110042366A (ko) 2008-08-18 2011-04-26 팀 아카데미 오브 파마슈티컬 사이언스 위장체류 약물 전달 시스템, 제작 방법 및 그것들의 사용
WO2011125075A2 (en) 2010-04-08 2011-10-13 Fdc Limited A novel gastroretentive delivery of macrolide
EP2415460A1 (de) * 2010-08-03 2012-02-08 ratiopharm GmbH Orale Darreichungsform von Pregabalin
TWI732337B (zh) * 2014-06-20 2021-07-01 美商梅琳塔有限責任公司 醫藥組成物及其用途
US11504324B2 (en) 2014-11-19 2022-11-22 DuPont Nutrition USA, Inc. Nanosuspension formulation
DK3648747T3 (da) * 2017-06-16 2022-11-28 Amneal Complex Products Res Llc Gastroretentive doseringsformer til vedvarende frigivelse af lægemidler
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
EP4056172A1 (en) 2018-06-18 2022-09-14 Amneal Complex Products Research LLC Extended release compositions comprising pyridostigmine
US10744083B2 (en) 2018-06-27 2020-08-18 Kashiv Biosciences, Llc Self-regulating osmotic gastroretentive drug delivery systems
CN110448535A (zh) * 2019-09-04 2019-11-15 湖南宇山玉月农业科技有限公司 一种裂褶菌素胃漂浮片
CN111116794A (zh) * 2019-12-20 2020-05-08 蚌埠市鑫晟新材料科技有限公司 一种中性造纸用聚合材料的制备方法
CN115715765A (zh) * 2021-08-24 2023-02-28 江苏万邦生化医药集团有限责任公司 一种悬浮片剂
CN113768898A (zh) * 2021-09-14 2021-12-10 江苏万邦生化医药集团有限责任公司 悬浮的胶囊片

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0798742B2 (ja) * 1986-07-03 1995-10-25 ゼリア新薬工業株式会社 徐放性製剤組成物
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
JPH0624959A (ja) * 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤

Also Published As

Publication number Publication date
CA2343760A1 (en) 2000-03-23
EA200300847A1 (ru) 2003-12-25
DK1107741T3 (da) 2003-11-17
SI1107741T1 (en) 2004-02-29
NO20011276D0 (no) 2001-03-13
NZ510487A (en) 2003-04-29
AR022672A1 (es) 2002-09-04
EA004443B1 (ru) 2004-04-29
PL346798A1 (en) 2002-02-25
CN1186013C (zh) 2005-01-26
NO20011276L (no) 2001-05-10
DE69909801D1 (de) 2003-08-28
MY127952A (en) 2007-01-31
CZ2001901A3 (cs) 2001-08-15
MXPA01002634A (es) 2002-06-04
AU1779499A (en) 2000-04-03
CO5130022A1 (es) 2002-02-27
BG105339A (en) 2001-11-30
AP2001002098A0 (en) 2001-03-31
ES2204098T3 (es) 2004-04-16
DE69909801T2 (de) 2004-06-03
OA11652A (en) 2004-12-08
CU23040A3 (es) 2005-04-14
HK1037967A1 (en) 2002-03-01
WO2000015198A1 (en) 2000-03-23
ID29843A (id) 2001-10-18
TR200100731T2 (tr) 2001-06-21
HRP20010187A2 (en) 2002-04-30
HUP0103632A2 (hu) 2002-02-28
CN1325299A (zh) 2001-12-05
AP1659A (en) 2006-09-06
ZA995839B (en) 2000-03-28
EP1107741A1 (en) 2001-06-20
AU758324B2 (en) 2003-03-20
NZ523747A (en) 2004-04-30
UA73287C2 (en) 2005-07-15
PT1107741E (pt) 2003-12-31
GEP20043216B (en) 2004-04-26
EA005767B1 (ru) 2005-06-30
HUP0103632A3 (en) 2005-06-28
EP1281397A1 (en) 2003-02-05
JP2002524494A (ja) 2002-08-06
IS5885A (is) 2001-03-12
EE200100153A (et) 2002-06-17
SK285478B6 (sk) 2007-02-01
SK3472001A3 (en) 2001-10-08
IL141977A0 (en) 2002-03-10
EA200100346A1 (ru) 2001-10-22
EP1107741B1 (en) 2003-07-23
BR9913696A (pt) 2001-10-09
SV1999000152A (es) 2000-07-03
PE20001058A1 (es) 2000-10-05
ATE245414T1 (de) 2003-08-15
HRP20010187B1 (en) 2004-04-30

Similar Documents

Publication Publication Date Title
UY25710A1 (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial
ES2330415T3 (es) Sistema para suministro osmotico de agentes activos farmaceuticos.
Timmins et al. Steady-state pharmacokinetics of a novel extended-release metformin formulation
US4695591A (en) Controlled release dosage forms comprising hydroxypropylmethylcellulose
ES2219709T3 (es) Un comprimido farmaceutico caracterizado porque presenta un gran aumento de volumen cuando entra en contacto con fluidos biologicos.
Krishnaiah et al. Studies on the development of oral colon targeted drug delivery systems for metronidazole in the treatment of amoebiasis
US7674480B2 (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
AU2001268722B8 (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
ES2618603T3 (es) Formulaciones de liberación modificada de metilfenidato
ES2398348T3 (es) Sistema de administración de fármacos controlada por retención gástrica
US8728521B2 (en) Physically/molecularly distributed and/or chemically bound medicaments in empty, hard capsule shells
YU19501A (sh) Sistem za kontrolisano davanje lekova oralnim putem koji obezbeđuje vremensku i prostornu kontrolu
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
DE60005819D1 (de) Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
NO982302L (no) Farmas°ytisk sammensetning
AR004391A1 (es) Formulacion de liberacion controlada para farmacos basicos escasamente solubles.
EP1275381A4 (en) SOLID COATED PREPARATIONS WITH TEMPERATURE RELEASE FOR ORAL ADMINISTRATION
KR20090065524A (ko) 프로그래머블 부력전달기술
AU2002303897A1 (en) System for osmotic delivery of pharmaceutically active agents
KR880010758A (ko) 서방성 제제
US20110287096A1 (en) Modified gastroretentive drug delivery system for amine drugs
Tiwari et al. Oral drug delivery system: a review
PT96921B (pt) Dispositivo de libertacao intermitente
EP0716595B1 (en) Dispenser containing hydrophobic agent
Kumar et al. Colon specific drug delivery by pH sensitive polymers & pulsatile drug delivery system

Legal Events

Date Code Title Description
ABAN Application deemed to be withdrawn (no publication fee paid)

Effective date: 20081203